Understanding how genes affect immune responses in lymphoma treatment
Official title: Integrative approach to identify genomic features that shape the immune landscape and predict immunotherapy response in diffuse large B cell lymphoma
Funded at University of Chicago · NIH-11079518 · Data updated 2026-11-12
This study is looking at how the immune system interacts with diffuse large B cell lymphoma (DLBCL) to find out which genetic traits might help predict how well patients will respond to immunotherapy, so that treatments can be better tailored for those whose cancer has come back or hasn’t responded to other treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $367,186 |
| NIH project number | 5R01CA273241-03 |
| Project ID | NIH-11079518 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with relapsed or refractory diffuse large B cell lymphoma.
✕Less likely to help
Patients with other types of lymphoma or those who are not relapsed or refractory may not benefit from this research.
What this research studies
This research investigates the immune landscape of diffuse large B cell lymphoma (DLBCL) to identify genomic features that may predict how well patients respond to immunotherapy. By analyzing gene expression in tumor samples, the study aims to classify the immune environment as either 'inflamed' or 'non-inflamed', which can influence treatment outcomes. The research will utilize advanced techniques to explore the relationship between genetic alterations in cancer cells and the immune response, potentially guiding personalized treatment strategies for patients with relapsed or refractory DLBCL.
Why it matters
Potential benefit: If successful, this research could lead to improved identification of patients who are likely to benefit from immunotherapy, enhancing treatment outcomes.
How similar studies have gone: Previous research has shown promise in characterizing immune landscapes in other cancers, suggesting potential for success in this approach for DLBCL.
Where this research is happening
-
University of Chicago
Chicago, United States Active
Researchers
- Principal investigator: Kline, Justin P. — University of Chicago
- Study coordinator: Kline, Justin P.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Immunotherapy for B-cell lymphoma using NK T cells
A patient-focused immunotherapy approach using natural killer T cells engineered to target B-cell lymphoma, potentially offering off-the-shelf treatment options.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.